studies

990A AASLD ABSTRACTS HEPATOLOGY, October, 2015
ALT or AST levels, platelet counts, HBsAg levels, or HBeAg
prevalence were similar between HDV positive and negative
participants. Conclusions: HDV coinfection was infrequent
(~3%) among adults in this North American HBV cohort. A distinctive
risk profile for acquisition was not apparent, highlighting
the challenges in using a risk-based screening algorithm to
identify HDV-infected adults.
Laboratory/Viral Features
*median (range)
Disclosures:
Norah Terrault - Advisory Committees or Review Panels: Eisai, Biotest; Consulting:
BMS, Merck, Achillion; Grant/Research Support: Eisai, Biotest, Vertex,
Gilead, AbbVie, Novartis, Merck
Adrian M. Di Bisceglie - Advisory Committees or Review Panels: Gilead, AbbVie,
Novartis, Bayer, BTG; Grant/Research Support: Gilead, AbbVie
Michael W. Fried - Consulting: Merck, Abbvie, Janssen, Bristol Myers Squibb,
Gilead; Grant/Research Support: Merck, AbbVie, Janssen, Bristol Myers Squibb,
Gilead; Patent Held/Filed: HCCPlex
Steven H. Belle - Grant/Research Support: Rottapharm!Madaus
The following authors have nothing to disclose: Marc G. Ghany, Chaeryon Kang,
Stewart Cooper, Jay H. Hoofnagle
1599
Comparative Study for Anti-Hepatitis B Surface Antigen
Titers Based on Two Measurement Methods: Using
Monoclonal Antibodies Isolated from Hepatitis B Vaccinated
Japanese Recipients.
Takako Inoue 1 , Shuko Murakami 2 , Susumu Tsutsumi 2 , Kumiko
Ohne 1 , Kazuto Tajiri 3 , Hiroyuki Kishi 4 , Shintaro Ogawa 2 , Noboru
Shinkai 5 , Takaaki Goto 1 , Yukio Wakimoto 1 , Yasuhito Tanaka 2,1 ;
1 Clinical Laboratory, Nagoya City University Hospital, Nagoya,
Japan; 2 Department of Virology & Liver unit, Nagoya City University
Graduate School of Medical Sciences, Nagoya, Japan;
3 Department of Immunology, University of Toyama, Toyama, Japan;
4 Department of Immunology, Graduate School of Medicine and
Pharmaceutical Sciences, University of Toyama, Toyama, Japan;
5 Department of Gastroenterology and Metabolism, Nagoya City
University Graduate School of Medical Sciences, Nagoya, Japan
Background: Since anti-hepatitis B surface antigen (anti-HBs)
titers are various depending on measurement methods, we
compared two different methods to quantity anti-HBs titers in
sera and HBs monoclonal antibodies. Methods: 1) The measurement
of anti-HBs was compared using either Lumipulse
G1200 (Fujirebio Inc.) or Architect i2000SR (Abbott Japan).
Previously, we isolated human monoclonal antibodies (mAbs)
against HBV from Japanese healthy volunteers who had been
immunized with a genotype C recombinant HBV vaccine
(Biimugen, Kaketsuken), using a cell-microarray system. A following
report revealed that among these mAbs, HB0116 and
HB0478, recognize the first N-terminal peptide loop within
the “a” determinant and have HBV-neutralizing activities. In
this study, HB0116, HB0478 and four other mAbs were used.
2) The sera from 182 HBV-resolved patients in our hospital,
who were negative for hepatitis B surface antigen (HBsAg)
but positive for anti-hepatitis B core antigen (anti-HBc) and/or
anti-HBs, were obtained. This study protocol was approved by
the appropriate institutional ethics review committees. Results:
1) Measuring 2 mAbs (HB0116 and HB0478) with HBV-neutralizing
activities, the anti-HBs titers of HB0116 (1.0 μg/mL)
were comparable (440.7 mIU/mL by Architect and 689.3
mIU/mL by Lumipulse), whereas those of HB0478 (1.0 mg/
mL) were much lower by Architect than by Lumipulse (42.6
mIU/mL by Architect and 818.6 mIU/mL by Lumipulse). Of
the other 4 mAbs without HBV-neutralizing activities, equal
titers were observed for one; two mAbs had less anti-HBs titers
by Architect; and one was below the cut-off index (